BOSTON SCIENTIFIC CORP·4

Feb 18, 5:58 PM ET

O'Connor Padraig Andrew 4

4 · BOSTON SCIENTIFIC CORP · Filed Feb 18, 2026

Research Summary

AI-generated summary of this filing

Updated

Boston Scientific (BSX) EVP Padraig O'Connor Exercises RSUs, Sells Shares for Taxes

What Happened
Padraig Andrew O'Connor, EVP Global Operations at Boston Scientific (BSX), had restricted stock units (RSUs) convert to common shares on Feb 13, Feb 14 and Feb 16, 2026. In total he received 2,595 shares (500 + 1,190 + 905). To satisfy tax withholding obligations, 987 of those shares were withheld/disposed (199 + 449 + 339) at an indicated per-share withholding value of $74.73, totaling approximately $73,758. The net result is an increase of 1,608 shares in his holdings (2,595 acquired − 987 withheld).

Key Details

  • Transaction types/codes: M = conversion/exercise of derivative (RSU conversion); F = shares withheld to pay tax liability.
  • Dates and amounts:
    • Feb 13, 2026: 500 RSUs converted → 199 shares withheld for taxes at $74.73 ($14,871).
    • Feb 14, 2026: 1,190 RSUs converted → 449 shares withheld for taxes at $74.73 ($33,554).
    • Feb 16, 2026: 905 RSUs converted → 339 shares withheld for taxes at $74.73 ($25,333).
  • Total shares converted: 2,595. Total withheld/disposed for taxes: 987 shares (~$73,758). Net shares acquired: +1,608.
  • Footnotes explain these were RSUs (each represents a commitment to issue one share) with vesting/issuance schedules (footnotes F1–F4 describe grant and installment dates).
  • Filing: Form 4 was filed Feb 18, 2026, reporting transactions with period of report Feb 13, 2026. This appears to be filed one business day late for the Feb 13/14 transactions (Form 4 is normally due within two business days).

Context

  • These transactions reflect RSU vesting and standard tax-withholding share retention (not an open-market sale or purchase). The F entries indicate shares were surrendered/withheld to cover taxes rather than a separate cash sale.
  • Such withholding transactions are routine compensation-related events and do not necessarily signal an insider view on the company’s stock; they do, however, increase the insider's net share count by the post-withholding amount noted above.

Insider Transaction Report

Form 4
Period: 2026-02-13
O'Connor Padraig Andrew
EVP, Global Operations
Transactions
  • Exercise/Conversion

    Common Stock

    [F1]
    2026-02-13+5004,986 total
  • Tax Payment

    Common Stock

    2026-02-13$74.73/sh199$14,8714,787 total
  • Exercise/Conversion

    Common Stock

    [F1]
    2026-02-14+1,1905,977 total
  • Tax Payment

    Common Stock

    2026-02-14$74.73/sh449$33,5545,528 total
  • Exercise/Conversion

    Common Stock

    [F1]
    2026-02-16+9056,433 total
  • Tax Payment

    Common Stock

    2026-02-16$74.73/sh339$25,3336,094 total
  • Exercise/Conversion

    Restricted Stock Units

    [F1][F2]
    2026-02-135001,502 total
    Exp: 2029-02-13Common Stock (500 underlying)
  • Exercise/Conversion

    Restricted Stock Units

    [F1][F3]
    2026-02-141,1901,190 total
    Exp: 2027-02-14Common Stock (1,190 underlying)
  • Exercise/Conversion

    Restricted Stock Units

    [F1][F4]
    2026-02-169050 total
    Exp: 2026-02-16Common Stock (905 underlying)
Footnotes (4)
  • [F1]Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.
  • [F2]Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 13, 2026, the first anniversary of the date of grant.
  • [F3]Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 14, 2024, the first anniversary of the date of grant.
  • [F4]Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 16, 2023, the first anniversary of the date of grant.
Signature
/s/ Susan Thompson, Attorney-in-Fact|2026-02-18

Documents

1 file
  • 4
    doc4.xmlPrimary